Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kymera Therapeutics Inc KYMR

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small... see more

Recent & Breaking News (NDAQ:KYMR)

Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day

GlobeNewswire December 16, 2021

Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 13, 2021

Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations

GlobeNewswire December 6, 2021

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413

GlobeNewswire November 30, 2021

Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021

GlobeNewswire November 17, 2021

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

GlobeNewswire November 12, 2021

Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update

GlobeNewswire November 10, 2021

Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 4, 2021

Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences

GlobeNewswire November 1, 2021

Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers

GlobeNewswire October 27, 2021

Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th

GlobeNewswire October 20, 2021

Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit

GlobeNewswire October 13, 2021

Kymera Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewswire September 2, 2021

Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

GlobeNewswire August 6, 2021

Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality

GlobeNewswire July 29, 2021

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum

GlobeNewswire July 12, 2021

Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire July 6, 2021

Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire June 30, 2021

Kymera Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire June 28, 2021

Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism

GlobeNewswire June 28, 2021